Literature DB >> 16937333

Primary microparticles and agglomerates of morphine for nasal insufflation.

Paola Russo1, Cecilia Sacchetti, Irene Pasquali, Ruggero Bettini, Gina Massimo, Paolo Colombo, Alessandra Rossi.   

Abstract

The aim of this work was to study the characteristics of powders of morphine HCl suitable for nasal administration to be employed for pain treatment as alternative to injection. Primary microparticles of morphine were prepared by spray drying of aqueous drug solutions using sugars or sugar derivatives as drying protectors and particle shapers. The spray drying procedure modified morphine crystallinity making the substance amorphous and affecting its stability in dependence on the excipient employed. A tendency of the spray-dried powders to turn to varying degrees of yellow was observed. Tumbling the powder in a rotating pan allowed the agglomeration of the primary microparticles. Agglomerates were also obtained by tumbling a mixture of morphine crystals and spray-dried microparticles of excipients, with advantages for the stability of the preparation. A nasal device quantitatively insufflated all the morphine agglomerates. The in vitro transport of morphine through rabbit nasal mucosa was faster using nasal powders than with the saturated solution of morphine. Lactose was the most effective excipient for agglomerate manufacturing and delivery of spray-dried morphine. The agglomerates of morphine crystals mixed with mannitol/lecithin microparticles showed superior stability. However, the drug permeation through rabbit mucosa was slower than with spray-dried morphine microparticle agglomerates. (c) 2006 Wiley-Liss, Inc. and the American Pharmacists Association

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16937333     DOI: 10.1002/jps.20604

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  7 in total

Review 1.  Pharmaceutical particle engineering via spray drying.

Authors:  Reinhard Vehring
Journal:  Pharm Res       Date:  2007-11-28       Impact factor: 4.200

2.  Agglomerated oral dosage forms of artemisinin/β-cyclodextrin spray-dried primary microparticles showing increased dissolution rate and bioavailability.

Authors:  Anna Giulia Balducci; Enrico Magosso; Gaia Colombo; Fabio Sonvico; Nurzalina Abdul Karim Khan; Kah Hay Yuen; Ruggero Bettini; Paolo Colombo; Alessandra Rossi
Journal:  AAPS PharmSciTech       Date:  2013-05-24       Impact factor: 3.246

3.  Agglomerates containing pantoprazole microparticles: modulating the drug release.

Authors:  Renata P Raffin; Paolo Colombo; Fabio Sonvico; Alessandra Rossi; Denise S Jornada; Adriana R Pohlmann; Silvia S Guterres
Journal:  AAPS PharmSciTech       Date:  2009-03-25       Impact factor: 3.246

4.  Inhalable Spray-Freeze-Dried Powder with L-Leucine that Delivers Particles Independent of Inspiratory Flow Pattern and Inhalation Device.

Authors:  Hiroko Otake; Tomoyuki Okuda; Daiki Hira; Haruyoshi Kojima; Yasuhiro Shimada; Hirozazu Okamoto
Journal:  Pharm Res       Date:  2015-12-07       Impact factor: 4.200

5.  Nanospray drying as a novel technique for the manufacturing of inhalable NSAID powders.

Authors:  Rita Patrizia Aquino; Mariateresa Stigliani; Pasquale Del Gaudio; Teresa Mencherini; Francesca Sansone; Paola Russo
Journal:  ScientificWorldJournal       Date:  2014-12-16

6.  In vivo nose-to-brain delivery of the hydrophilic antiviral ribavirin by microparticle agglomerates.

Authors:  Alessandro Giuliani; Anna Giulia Balducci; Elisa Zironi; Gaia Colombo; Fabrizio Bortolotti; Luca Lorenzini; Viola Galligioni; Giampiero Pagliuca; Alessandra Scagliarini; Laura Calzà; Fabio Sonvico
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

7.  Structure and Fate of Nanoparticles Designed for the Nasal Delivery of Poorly Soluble Drugs.

Authors:  Adryana Rocha Clementino; Giulia Pellegrini; Sabrina Banella; Gaia Colombo; Laura Cantù; Fabio Sonvico; Elena Del Favero
Journal:  Mol Pharm       Date:  2021-07-14       Impact factor: 4.939

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.